David A. Braun, Ph.D.
Affiliations: | 2012 | Program in Computational Biology | New York University, New York, NY, United States |
Area:
Cell Biology, Immunology, Molecular BiologyGoogle:
"David Braun"Parents
Sign in to add mentor| Stuart C. Sealfon | grad student | 2012 | NYU | |
| (Temporal Pattern of STAT3 Activation Codes for Specific Cytokine Response.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Saliby RM, El Zarif T, Bakouny Z, et al. (2023) Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. Cancer Immunology Research |
| Atkins MB, Jegede OA, Haas NB, et al. (2022) Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102938 |
| Bi K, He MX, Bakouny Z, et al. (2021) Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell |
| McGregor BA, Lalani AA, Xie W, et al. (2020) Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal of Cancer (Oxford, England : 1990). 135: 203-210 |
| Braun DA, Hou Y, Bakouny Z, et al. (2020) Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine |
| Abou Alaiwi S, Nassar AH, Xie W, et al. (2020) Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunology Research |
| Mahoney KM, Ross-Macdonald PB, Shukla SA, et al. (2020) Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer. Journal of Clinical Oncology. 38: 746-746 |
| Flippot R, Bakouny Z, Wei XX, et al. (2020) Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial. Journal of Clinical Oncology. 38: 740-740 |
| Bakouny Z, Braun DA, Shukla SA, et al. (2020) Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI). Journal of Clinical Oncology. 38: 715-715 |
| Ficial M, Jegede O, Sant'Angelo M, et al. (2020) Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. Journal of Clinical Oncology. 38: 5023-5023 |